Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIB Pilot Study to Confirm the Feasibility and Tolerability of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia

NCT02016755 is registered in ClinicalTrials.gov with AnGes USA, Inc. as lead sponsor.

NCT NCT02016755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02016755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIB Pilot Study to Confirm the Feasibility and Tolerability of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
Lead sponsor
AnGes USA, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2013
Completion date
March 31, 2018
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

critical limb ischemia, peripheral arterial disease, vascular diseases